| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 209.31 | 2.5% | 10.9% |
| Total Income | 209.31 | 2.5% | 10.9% |
| Expenditure | 238.86 | 25.6% | 38.9% |
| PBT | -26.81 | 289.5% | 256.7% |
| Net Profit | -38.43 | 867.1% | 357.8% |
| OPM | -14.12% | 20.96pp | 23.03pp |
| NPM | -18.36% | 20.81pp | 26.26pp |
| EPS | -0.68 | 855.6% | 351.9% |
Repligen Reports Q3 2026 Financial Results and Updates Full Year 2026 Guidance
27 Oct 2026 · 27 Oct, 4:37 pm
Summary
Repligen Corporation announced strong third quarter 2026 financial results, with revenue reaching $209 million, an 11% increase year-over-year. The company also raised its full-year 2026 guidance, now expecting reported revenue between $844 million and $852 million. Management expressed confidence due to strong year-to-date performance, continued order momentum, and the recent acquisition of BioLife Solutions, which is expected to enhance long-term growth and margin profile.
Key Highlights
- 1
Repligen reported third quarter revenue of $209 million, an 11% increase as reported and 12.5% organic year-over-year.
- 2
The company raised its full-year 2026 revenue guidance to $844-$852 million, representing reported revenue growth of 14.5% - 15.5%.
- 3
Q3 2026 adjusted operating margin was 15.9%, an improvement from 14.2% in the prior year.
- 4
Adjusted EBITDA margin for Q3 2026 was 20.9%, up from 19.0% in Q3 2025.
- 5
The BioLife acquisition was closed in October, fast-tracking Repligen's leadership in the cell therapy market.
- 6
A new Repligen Training & Innovation Center (RTIC) was opened in Seoul, South Korea on October 23, 2026.
Management Comments
Olivier Loeillot
We delivered a record third quarter, with $209 million in revenue and 12.5% organic growth, driven by continued strength across our diversified portfolio. End-market demand continues to improve, with healthy trends in consumables and services complemented by a growing capital equipment order book. The completion of the BioLife acquisition in October marks a significant milestone for Repligen, and integration is progressing well. Early customer feedback has been very encouraging, and we have already taken actions to realize a sizable portion of our expected operating expense synergies. Our strong year-to-date performance, continued order momentum and the addition of BioLife give us confidence to raise our full-year guidance again.
Informational and educational content only. Not investment advice.